Overall outcome and survival rates of lower limb malignancies have improved rapidly since the 1970s due to improved (neo) adjuvant chemotherapy and limb-salvaging procedures [1, 2, 3]. However, the severe femoral bone loss and extensive soft tissue damage that is associated with limb-salvaging surgery and complications of arthroplasty required the development of megaprostheses